2018 Deep Vein Thrombosis Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Deep Vein Thrombosis Market
Thrombosis refers to a serious heart condition in which arteries or veins are blocked because of blood clot in the blood vessel. Based on the location of clot, it is classified as Venous and Arterial Thromboembolism.
Venous Thromboembolism (VTE) is classified further as deep vein thrombosis (DVT) and pulmonary embolism (PE). In DVT, the clot in veins lies deep inside muscled while in PE, the clot is nearby lungs.
An estimated 10 million population is affected by Thromobisis worldwide every year.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Deep Vein Thrombosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Deep Vein Thrombosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Deep Vein Thrombosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Venous Thromboembolism (VTE) is classified further as deep vein thrombosis (DVT) and pulmonary embolism (PE). In DVT, the clot in veins lies deep inside muscled while in PE, the clot is nearby lungs.
An estimated 10 million population is affected by Thromobisis worldwide every year.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Deep Vein Thrombosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Deep Vein Thrombosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Deep Vein Thrombosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 DEEP VEIN THROMBOSIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Deep Vein Thrombosis Pipeline Snapshot
2.3 Deep Vein Thrombosis Pipeline by Phase
2.4 Deep Vein Thrombosis Pipeline by Company
2.5 Deep Vein Thrombosis Pipeline by Mechanism of Action
3 DEEP VEIN THROMBOSIS- COMPANY WISE PIPELINE ANALYSIS
Bayer AG
CarboMimetics
Daiichi Sankyo, Inc.
Dong-A Socio Holdings Co Ltd
Genentech, Inc.
Generex Biotechnology Corp
GlycoMimetics, Inc.
Laboratorios Farmaceuticos Rovi SA
4 DEEP VEIN THROMBOSIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN DEEP VEIN THROMBOSIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 DEEP VEIN THROMBOSIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Deep Vein Thrombosis Pipeline Snapshot
2.3 Deep Vein Thrombosis Pipeline by Phase
2.4 Deep Vein Thrombosis Pipeline by Company
2.5 Deep Vein Thrombosis Pipeline by Mechanism of Action
3 DEEP VEIN THROMBOSIS- COMPANY WISE PIPELINE ANALYSIS
Bayer AG
CarboMimetics
Daiichi Sankyo, Inc.
Dong-A Socio Holdings Co Ltd
Genentech, Inc.
Generex Biotechnology Corp
GlycoMimetics, Inc.
Laboratorios Farmaceuticos Rovi SA
4 DEEP VEIN THROMBOSIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN DEEP VEIN THROMBOSIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Deep Vein Thrombosis Pipeline by Phase, H2- 2018
Figure 2: Deep Vein Thrombosis Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Deep Vein Thrombosis Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Deep Vein Thrombosis Pipeline by Phase, H2- 2018
Figure 2: Deep Vein Thrombosis Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Deep Vein Thrombosis Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Deep Vein Thrombosis Pipeline by Phase, H2- 2018
Deep Vein Thrombosis Pipeline by Companies, H2- 2018
Deep Vein Thrombosis Pipeline by Mechanism of Action, H2- 2018
Table 1: Bayer AG Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 2: CarboMimetics Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 3: Daiichi Sankyo, Inc. Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 4: Dong-A Socio Holdings Co Ltd Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 5: Genentech, Inc. Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 6: Generex Biotechnology Corp Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 7: GlycoMimetics, Inc. Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 8: Laboratorios Farmaceuticos Rovi SA Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Deep Vein Thrombosis Pipeline by Phase, H2- 2018
Deep Vein Thrombosis Pipeline by Companies, H2- 2018
Deep Vein Thrombosis Pipeline by Mechanism of Action, H2- 2018
Table 1: Bayer AG Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 2: CarboMimetics Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 3: Daiichi Sankyo, Inc. Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 4: Dong-A Socio Holdings Co Ltd Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 5: Genentech, Inc. Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 6: Generex Biotechnology Corp Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 7: GlycoMimetics, Inc. Deep Vein Thrombosis Pipeline Drugs, H2- 2018
Table 8: Laboratorios Farmaceuticos Rovi SA Deep Vein Thrombosis Pipeline Drugs, H2- 2018
